Home  »  Trending   »  Can Takeda Pharmaceutical Company Limited (TAK) Re...

Can Takeda Pharmaceutical Company Limited (TAK) Remain Competitive?

Takeda Pharmaceutical Company Limited (NYSE:TAK) went down by -0.37% from its latest closing price compared to the recent 1-year high of $16.30. The company’s stock price has collected -0.12% of loss in the last five trading sessions. The Wall Street Journal reported on 12/20/21 that Pandemic Trades Roar Back: What to Watch in the Stock Market Today

Is It Worth Investing in Takeda Pharmaceutical Company Limited (NYSE :TAK) Right Now?

Takeda Pharmaceutical Company Limited (NYSE:TAK) scored a price-to-earnings ratio above its average ratio, recording 30.26 x from its present earnings ratio. Plus, the 36-month beta value for TAK is at 0.68. Opinions of the stock are interesting as 5 analysts out of 14 who provided ratings for Takeda Pharmaceutical Company Limited declared the stock was a “buy,” while 1 rated the stock as “overweight,” 7 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $17.14, which is $1.5 above the current price. TAK currently public float of 3.07B and currently shorts hold a 0.24% ratio of that float. Today, the average trading volume of TAK was 2.86M shares.

TAK’s Market Performance

TAK stocks went down by -0.12% for the week, with a monthly jump of 4.74% and a quarterly performance of 27.21%, while its annual performance rate touched 10.03%. The volatility ratio for the week stands at 1.08% while the volatility levels for the past 30 days are set at 1.14% for Takeda Pharmaceutical Company Limited. The simple moving average for the period of the last 20 days is 2.51% for TAK stocks with a simple moving average of 13.89% for the last 200 days.

Analysts’ Opinion of TAK

Many brokerage firms have already submitted their reports for TAK stocks, with Cowen repeating the rating for TAK by listing it as a “Outperform.” The predicted price for TAK in the upcoming period, according to Cowen is $24 based on the research report published on July 19th of the previous year 2022.

TAK Trading at 7.44% from the 50-Day Moving Average

After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.04% of loss for the given period.

Volatility was left at 1.14%, however, over the last 30 days, the volatility rate increased by 1.08%, as shares surge +4.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.01% upper at present.

During the last 5 trading sessions, TAK fell by -0.12%, which changed the moving average for the period of 200-days by +9.95% in comparison to the 20-day moving average, which settled at $15.77. In addition, Takeda Pharmaceutical Company Limited saw 3.40% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for TAK

Current profitability levels for the company are sitting at:

  • +17.11 for the present operating margin
  • +57.26 for the gross margin

The net margin for Takeda Pharmaceutical Company Limited stands at +6.45. The total capital return value is set at 5.89, while invested capital returns managed to touch 2.25. Equity return is now at value 3.50, with 1.60 for asset returns.

Based on Takeda Pharmaceutical Company Limited (TAK), the company’s capital structure generated 84.65 points at debt to equity in total, while total debt to capital is 45.84. Total debt to assets is 36.51, with long-term debt to equity ratio resting at 80.11. Finally, the long-term debt to capital ratio is 43.39.

When we switch over and look at the enterprise to sales, we see a ratio of 2.79, with the company’s debt to enterprise value settled at 0.51. The receivables turnover for the company is 4.64 and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.